153 related articles for article (PubMed ID: 15536687)
1. ERBB2 kinase mutations in lung-cancer tumours.
Senior K
Lancet Oncol; 2004 Nov; 5(11):647. PubMed ID: 15536687
[No Abstract] [Full Text] [Related]
2. Mutations in the epidermal growth factor receptor tyrosine kinase may predict response to gefitinib in non-small-cell lung cancer.
Clin Lung Cancer; 2004 May; 5(6):331-2. PubMed ID: 15217530
[No Abstract] [Full Text] [Related]
3. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Lynch TJ; Bell DW; Sordella R; Gurubhagavatula S; Okimoto RA; Brannigan BW; Harris PL; Haserlat SM; Supko JG; Haluska FG; Louis DN; Christiani DC; Settleman J; Haber DA
N Engl J Med; 2004 May; 350(21):2129-39. PubMed ID: 15118073
[TBL] [Abstract][Full Text] [Related]
4. [Tumor response to gefitinib (IRESSA) in pulmonary adenocarcinoma: toward a molecular basis for therapeutic targetting].
Madelaine J; Cadranel J; Zalcman G
Rev Mal Respir; 2004 Nov; 21(5 Pt 1):881-5. PubMed ID: 15622331
[No Abstract] [Full Text] [Related]
5. Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial.
Price N; Belani C
Clin Lung Cancer; 2005 Jan; 6(4):214-6. PubMed ID: 15694012
[No Abstract] [Full Text] [Related]
6. Targeted therapies: Tyrosine-kinase inhibitors--new standard for NSCLC therapy.
Saijo N
Nat Rev Clin Oncol; 2010 Nov; 7(11):618-9. PubMed ID: 20981125
[No Abstract] [Full Text] [Related]
7. Lung cancer: intragenic ERBB2 kinase mutations in tumours.
Stephens P; Hunter C; Bignell G; Edkins S; Davies H; Teague J; Stevens C; O'Meara S; Smith R; Parker A; Barthorpe A; Blow M; Brackenbury L; Butler A; Clarke O; Cole J; Dicks E; Dike A; Drozd A; Edwards K; Forbes S; Foster R; Gray K; Greenman C; Halliday K; Hills K; Kosmidou V; Lugg R; Menzies A; Perry J; Petty R; Raine K; Ratford L; Shepherd R; Small A; Stephens Y; Tofts C; Varian J; West S; Widaa S; Yates A; Brasseur F; Cooper CS; Flanagan AM; Knowles M; Leung SY; Louis DN; Looijenga LH; Malkowicz B; Pierotti MA; Teh B; Chenevix-Trench G; Weber BL; Yuen ST; Harris G; Goldstraw P; Nicholson AG; Futreal PA; Wooster R; Stratton MR
Nature; 2004 Sep; 431(7008):525-6. PubMed ID: 15457249
[TBL] [Abstract][Full Text] [Related]
8. The epidermal growth factor receptor-tyrosine kinase inhibitor era has changed the causes of death of patients with advanced non-small-cell lung cancer.
Wu WS; Chen YM; Tsai CM; Shih JF; Lee YC; Perng RP; Whang-Peng J
J Chin Med Assoc; 2013 Dec; 76(12):682-5. PubMed ID: 24064329
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
10. EGFR mutations in non-small cell lung carcinomas may predict response to gefitinib: extension of an emerging paradigm.
Chang KL; Lau SK
Adv Anat Pathol; 2005 Mar; 12(2):47-52. PubMed ID: 15731572
[No Abstract] [Full Text] [Related]
11. Gefitinib: phase II and III results in advanced non-small cell lung cancer.
Kelly K; Averbuch S
Semin Oncol; 2004 Feb; 31(1 Suppl 1):93-9. PubMed ID: 14981586
[TBL] [Abstract][Full Text] [Related]
12. EGFR mutations and sensitivity to gefitinib.
Rossi G; Marchioni A; Longo L
N Engl J Med; 2004 Sep; 351(12):1260-1; author reply 1260-1. PubMed ID: 15376351
[No Abstract] [Full Text] [Related]
13. Gefitinib--a novel targeted approach to treating cancer.
Herbst RS; Fukuoka M; Baselga J
Nat Rev Cancer; 2004 Dec; 4(12):956-65. PubMed ID: 15573117
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase signal transduction inhibitors. Clinical trials.
Scagliotti GV
Suppl Tumori; 2002; 1(4):S34-6. PubMed ID: 12415814
[No Abstract] [Full Text] [Related]
15. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.
Han SW; Kim TY; Jeon YK; Hwang PG; Im SA; Lee KH; Kim JH; Kim DW; Heo DS; Kim NK; Chung DH; Bang YJ
Clin Cancer Res; 2006 Apr; 12(8):2538-44. PubMed ID: 16638863
[TBL] [Abstract][Full Text] [Related]
16. Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
Stinchcombe TE; Ramalingam SS
Lancet Oncol; 2010 Jun; 11(6):500-1. PubMed ID: 20493770
[No Abstract] [Full Text] [Related]
17. Second/third/fourth line therapy with tyrosine kinase inhibitors in NSCLC.
Van Zandwijk N; Baas P
Suppl Tumori; 2002; 1(4):S37-8. PubMed ID: 12415815
[No Abstract] [Full Text] [Related]
18. Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations.
Ichihara E; Hotta K; Takigawa N; Kudo K; Kato Y; Honda Y; Hayakawa H; Minami D; Sato A; Tabata M; Tanimoto M; Kiura K
Lung Cancer; 2013 Sep; 81(3):435-439. PubMed ID: 23809059
[TBL] [Abstract][Full Text] [Related]
19. EGFR and erbB2 mutation status in Japanese lung cancer patients.
Sasaki H; Shimizu S; Endo K; Takada M; Kawahara M; Tanaka H; Matsumura A; Iuchi K; Haneda H; Suzuki E; Kobayashi Y; Yano M; Fujii Y
Int J Cancer; 2006 Jan; 118(1):180-4. PubMed ID: 16003726
[TBL] [Abstract][Full Text] [Related]
20. Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer.
Cho D; Kocher O; Lee JC; Tenen DG; Meyerson ML; Janne PA; Halmos B
J Clin Oncol; 2005 Jan; 23(1):235-7. PubMed ID: 15625379
[No Abstract] [Full Text] [Related]
[Next] [New Search]